Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34(−) and immature CD34(+) cells

Accumulation in target cells is an essential pharmacokinetic step of targeted therapies. Tyrosine Kinase Inhibitors (TKI) against the BCR-ABL fusion protein in Chronic Phase-Chronic Myeloid Leukaemia (CP-CML) cells constitute a unique model in terms of efficacy, specificity, and in vivo demonstratio...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Berger, Marc G., Lebecque, Benjamin, Tassin, Thomas, Dannus, Louis-Thomas, Berger, Juliette, Soucal, Mélanie, Guerci, Agnès, Cony-Makhoul, Pascale, Johnson, Hyacinthe, Etienne, Gabriel, Guyotat, Denis, Gagnieu, Marie-Claude, Pereira, Bruno, Saugues, Sandrine, Tournilhac, Olivier, Hermet, Eric, Bourgne, Céline
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7969931/
https://ncbi.nlm.nih.gov/pubmed/33731863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-85734-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars